Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Wat is de waarde van uniQure?
Volgen
HemA: well served market, feedback regulatory bodies, competitive landscape, clinical feasibility, partner interest: interest did not materialize. Fix-Super9 X Streep erdoor miQURE #SCA3 -> #SCA2 #SCA1 HD, next generation.twitter.com/floszcrxl/status/12759253...
flosz schreef op 25 juni 2020 00:59 :
[...]
Fabry + nog wat in de maak (?)
Waarom niet. Opvallend hoe QURE altijd verrast. BMS deal viel uit de lucht, Padua manoeuvre ook en nu dit. Volgende move waarschijnlijk even onverwacht. Saai zijn ze in ieder geval niet, gaan helemaal hun eigen weg.
Geweldig NIEUWS !!! Verwacht vanmiddag een hogere Koers. $ 105,- ???
Nounou verwacht eerder dat we naar de 50 dollar gaan vandaag
Dit is toch een beteren deal dan die van Spark Spark Therapeutics to receive up to an additional $25 million per terms of amendment
Under the terms of the agreement, Spark will receive an upfront payment of $20 million and will be eligible for additional development and commercialization milestone payments of up to $260 million for multiple hemophilia B product candidates that may be developed under the collaboration. Spark will be responsible for conducting all Phase 1/2 studies while Pfizer will assume responsibility for pivotal studies, any regulatory approvals and potential global commercialization of the product. Spark is entitled to receive double-digit royalties based on global product sales.
Stefano schreef op 25 juni 2020 10:47 :
Niet voor de belegerd
Natuurlijk wel, voor de beleger ook.
SunTrust Robinson Humphrey BUY QURE: CSL deal takes Company in a great direction and pushes out M&A until CNS update What's Incremental To Our View We believe the CSL license agreement for EtranaDez in hemophilia B takes the Company in a great direction and pushes out M&A until we get color from Huntington's. We recommend buying QURE on the weakness. We’ve updated our model to incorporate terms of the license agreement: (i) hemophilia B is now recognized as royalties, and we give credit to (ii) $450M upfront cash and (iii) to additional $850M in milestone payments—$300M based on regulatory and first commercial and $550M on additional sales—from potential $1.6B. We believe open-label design of pivotal HOPE-B trial in hemophilia B would allow CSL to see data and help with license agreement as well as quell some investor concerns over immunogenicity risk with not excluding patients with pre-existing neutralizing Abs. • Bodes well for success of topline data expected in YE20 • All 54 patients have achieved 12 weeks of follow-up • First patient has gone beyond 52 weeks • Topline 26-week data by YE20 • Given this and recent commentary from BioMarin (BMRN, BUY), we are increasing our pricing assumption of EtranaDez from $1.5M to $2M.We believe the decision to license is a smart strategy for QURE. • Deprioritizing hemophilia A is a good decision given the competitiveness in the market • We believe CSL could maximize value of EtranaDez in hemophilia B given CSL’s footprint in the space • Helps validate QURE’s platform and manufacturing and makes M&A more likely We believe the license agreement with CSL Behring (CSL-AU, NR) pushes out M&A until we get color from Huntington’s disease. CEO noted that the agreement helps validate the platform and manufacturing capability and could make QURE more attractive for acquisition, but we believe PoC in Huntington's disease from the clinic will increase strategic interest. Additionally noted for a strong M&A target would be having a strong lead program, which in our view is also supported by the license agreement with CSL for > $2B ($450M upfront and $1.6B in milestones).
We gaan het zien vanmiddag voor beurs is nu $53,40
Mooie prijs om nog wat bij te kopen.
Van twitter: $QURE just in @ #CreditSuisse: DEAL STRONGLY POSITIVE , PT 76 Outperform, eliminates the need for Co. to build a potentially expensive global hematology commercial infrastructure for a single hemophilia product. The deal also provides substantial upfront capital to focus on the lead candidate in Huntington’s disease (AMT-130) and additional gene therapy candidates in the CNS and liver-directed space. Expecting stable bottom floor @ $61-65 as regular trading resumes, giving it 2-3 business days.Finally, we believe the deal signals high confidence in the ongoing AMT-130 Ph1/2 trial in HD. $SNY $IBB $XBI 2 positieve analisten, CreditSuisse en SunTrust, de rest kan er vooralsnog geen sjokola van maken met koersdoelen tussen de 58-62. Hebben al hun klanten verkocht op het overname verhaal en moeten nu iets nieuws verzinnen, altijd lastig.
Ik zie het in de komende weken ook wel teruggaan richting de 60.
Inmiddels voorbeurs $52,48, daarom twijfel ik een beetje mijn plan om alle stukken die ik bezit er bij opening uit te gooien. Wat doen jullie?
pim f schreef op 25 juni 2020 13:26 :
Inmiddels voorbeurs $52,48, daarom twijfel ik een beetje mijn plan om alle stukken die ik bezit er bij opening uit te gooien. Wat doen jullie?
Blijf zitten
pim f schreef op 25 juni 2020 13:26 :
Inmiddels voorbeurs $52,48, daarom twijfel ik een beetje mijn plan om alle stukken die ik bezit er bij opening uit te gooien. Wat doen jullie?
Je moet het natuurlijk helemaal zelf weten, maar de kans bestaat dat je na verkoop tegen de openingskoers 51-53 de realiteit terugkeert tijdens de komende handelsuren en de koers weer ziet oplopen richting de 58-60. Maar dat blijft natuurlijk koffiedik kijken...
pim f schreef op 25 juni 2020 13:26 :
Inmiddels voorbeurs $52,48, daarom twijfel ik een beetje mijn plan om alle stukken die ik bezit er bij opening uit te gooien. Wat doen jullie?
Ik ga juist kopen! Had deze kans niet meer verwacht! Prima deal op de lange termijn.
Ja, ik ga ook zeker niet verkopen en probeer wat bij te kopen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,02
0,00%
EUR/USD
1,0709
+0,11%
FTSE 100
8.040,38
0,00%
Germany40^
18.086,70
-0,01%
Gold spot
2.317,58
+0,06%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers